NCT04109482: Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. |
|
|
| Terminated | 1/2 | 3 | US | MB-102, CD123 CAR-T, Fludarabine, Fludara, Cyclophosphamide, Cytoxan | Mustang Bio | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | 05/23 | 05/23 | | |
NCT05645744: Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. |
|
|
| Terminated | N/A | 3 | US | Prior MB-102 CAR-T cell investigational product., Prior MB-106 CAR-T cell investigational product. | Mustang Bio | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse, Small Lymphocytic Lymphoma, Relapsed, Waldenstrom's Macroglobulinemia Recurrent, Follicular B-cell Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory, Mantle Cell Lymphoma Recurrent, Hairy Cell Leukemia, Diffuse Large B Cell Lymphoma, Waldenstrom's Macroglobulinemia Refractory, Mantle Cell Lymphoma Refractory | 04/24 | 04/24 | | |
